Reversal of Hypoglycemia Unawareness Using Continuous Glucose Monitoring

Diabetes Mellitus Clinical Trial

Official title:

Reversal of Hypoglycemia Unawareness Using Continuous Glucose Monitoring

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00796848
• Other study ID #: SU-10172008-1323
• Secondary ID: Stanford eprotoc
• Status: Withdrawn
• Phase: N/A
• Start date: March 2009
• Est. completion date: March 2010

Study information

• Verified date: June 2018
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of doing this study is to see if continuous glucose monitoring can help people with type 1 diabetes who are sometimes unable to feel if they have a low blood glucose reading. For this study we will be using the Navigator Continuous Glucose Monitor. We think that your body may not have enough of a certain hormone that usually helps people know when they are going low. If you can keep from going low, we think there will be enough of that hormone to help you recognize the symptoms of a low before it happens.

Description:

To enroll in this study you must be between the ages of 7 and 20, have type 1 diabetes, and experience at least two episodes of low blood glucose readings weekly that you do not feel. Up to 25 subjects will be enrolled at Stanford and another 25 at the Barbara Davis Center in Colorado. The study will last approximately 8 months for each participant.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 7 Years to 20 Years

Eligibility

Inclusion Criteria:

1. Be at least 7 to 20 years old

2. Have been diagnosed with type 1 diabetes for at least 1 year

3. Report 2 or more episodes per week of asymptomatic hypoglycemia as determined by completion of the Hypoglycemia Awareness Questionnaire (HAQ) or as determined by Investigator

4. HbA1c level < 10%

5. Internet access for downloading continuous glucose monitoring (CGM), access to a compatible computer (Windows Vista is not compatible for downloading.)

6. For females, you are not intending to become pregnant during the study

7. No expectation that you will be moving out of the area for the duration of the study

Exclusion Criteria:

1. The presence of a significant medical disorder (including epilepsy, or any cause of seizures other than hypoglycemia) that in the judgment of the Investigator will affect the wearing of the sensors or the completion of any aspect of the protocol

2. Treatment with systemic or inhaled corticosteroids in the last six months

3. Inpatient psychiatric treatment in the past six months for you or your primary caregiver

4. Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the Investigator would be a contraindication to participation in the study

5. Having two or more severe hypoglycemia episodes (seizure or loss of consciousness) in the six months prior to enrollment

6. Having a severe hypoglycemic episode in the 30 days prior to enrollment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Hypoglycemia
• Unconsciousness

Intervention

Device:
• Navigator Continuous Glucose Monitor

Locations

Country	Name	City	State
United States	Stanford University School of Medicine	Stanford	California

Sponsors (2)

Lead Sponsor	Collaborator
Stanford University	University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the effectiveness of continuous glucose monitoring in the reduction of hypoglycemia unawareness.
Secondary	To assess the levels of epinephrine production in youth diagnosed with hypoglycemia unawareness with and without continuous glucose monitor wear.

External Links

•   Stanford Pediatric Endocrinology Department website